M&ALisata Therapeutics, Inc.Lisata acquires Marea Therapeutics, raises $225 million in private placementThe merger, announced September 17, 2026, pairs Lisata's clinical-stage pipeline with Marea's cardioendocrine candidates and is expected to fund operations into 2028.SEC filing
RestructuringLisata Therapeutics, Inc.Lisata cuts 72% of workforce, terminates CMO amid Kuva Labs merger disputeLisata Therapeutics slashed staff and lost its R&D chief on August 3, 2026, while suing Kuva Labs over an alleged breach of their merger agreement.SEC filing
PartnershipLisata Therapeutics, Inc.Lisata terminates Kuva Labs merger after failed financing for tender offerKuva Labs could not fund its $4.00-per-share tender offer, triggering termination of the deal and a $2 million fee owed to Lisata.SEC filing (2)
